Technology Bundle ID
TAB-3570

Novel Dual 5-lipoxgenase and East CYP51 Inhibitors for the Treatment of Dandruff

Applications
Linked ID
E-217-2013-0
Lead Inventors
Theodore Holman (University of California, Santa Cruz)
Co-Inventors
Ajit Jadhav (NCATS)
Anton Simeonov (NCATS)
David Maloney (NCATS)
Ganesha Rai Bantukallu (NCATS)
Steven Kelly (Swansea University)
ICs
This technology includes a newly designed chemical molecule that is both an antifungal agent, by inhibiting CYP51, and an anti-inflammatory agent, by inhibiting 5-lipoxygenase, for the treatment of dandruff. Both of these properties would be useful for antifungal treatments, and both of these attributes are required to combat dandruff. However, typical therapies involve treating the infection and inflammation separately.
Commercial Applications
Utilized for the treatment of dandruff.
Competitive Advantages
Single agent therapy for dandruff with a dual mechanism.

Request More Info

Licensing Contact: